|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
WO2006132670A2
(en)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
WO2008070593A2
(en)
|
2006-12-01 |
2008-06-12 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
|
BRPI0809435A2
(pt)
|
2007-03-27 |
2014-09-09 |
Sea Lane Biotechnologies, Llc |
Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
|
|
NZ583318A
(en)
|
2007-07-16 |
2012-07-27 |
Genentech Inc |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
|
RU2476441C2
(ru)
|
2007-10-19 |
2013-02-27 |
Сиэтл Дженетикс, Инк. |
Cd19-связывающие средства и их применение
|
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
US8163551B2
(en)
|
2008-05-02 |
2012-04-24 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
CN102482345A
(zh)
|
2009-05-13 |
2012-05-30 |
航道生物技术有限责任公司 |
针对流感病毒的中和分子
|
|
MY173390A
(en)
|
2009-10-23 |
2020-01-22 |
Takeda Pharmaceuticals Co |
Anti-gcc antibody molecules and related compositions and methods
|
|
AU2011213609B2
(en)
*
|
2010-02-08 |
2016-11-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
|
EP2542576B1
(en)
*
|
2010-03-02 |
2016-04-20 |
Seattle Genetics, Inc. |
Methods for screening antibodies
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
DK2608796T3
(en)
|
2010-08-05 |
2019-03-18 |
Seattle Genetics Inc |
Inhibition of protein fucosylation in vivo using fucose analogues
|
|
WO2012046745A1
(ja)
*
|
2010-10-04 |
2012-04-12 |
独立行政法人理化学研究所 |
Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
|
|
AU2011316917B2
(en)
|
2010-10-22 |
2016-02-25 |
Seagen Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
|
|
CA2822366A1
(en)
*
|
2010-12-23 |
2012-06-28 |
Janssen Biotech, Inc. |
Active protease-resistant antibody fc mutants
|
|
KR101820558B1
(ko)
|
2010-12-23 |
2018-02-28 |
유리타 아. 게. |
넓은 영역에 나노 구조체를 생산하기 위한 시스템 및 방법
|
|
DK2694111T3
(en)
*
|
2011-04-01 |
2016-10-10 |
Wyeth Llc |
Antibody pharmaceutical conjugates
|
|
WO2012171020A1
(en)
|
2011-06-10 |
2012-12-13 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
WO2013016714A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies |
Sur-binding proteins against erbb3
|
|
PL2744515T3
(pl)
|
2011-08-16 |
2022-05-30 |
Morphosys Ag |
Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
|
|
HUE058855T2
(hu)
|
2011-08-16 |
2022-09-28 |
Morphosys Ag |
Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
|
|
CN102343083A
(zh)
*
|
2011-10-17 |
2012-02-08 |
中国科学院成都生物研究所 |
一种抗病毒的组合药物
|
|
WO2013067581A1
(en)
*
|
2011-11-09 |
2013-05-16 |
Children's Cancer Institute Australia for Medical Research |
Cancer treatment
|
|
EP3446707A1
(en)
|
2011-12-22 |
2019-02-27 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
|
HK1204445A1
(en)
|
2012-01-20 |
2015-11-20 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
|
EP3575794A1
(en)
|
2012-02-10 |
2019-12-04 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
KR102557309B1
(ko)
|
2012-05-15 |
2023-07-20 |
씨젠 인크. |
자가-안정화 링커 접합체
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
JP6280546B2
(ja)
|
2012-06-26 |
2018-02-14 |
デル マー ファーマシューティカルズ |
ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
|
|
CN104507537A
(zh)
*
|
2012-07-13 |
2015-04-08 |
宾夕法尼亚大学董事会 |
用于调节car t细胞的组合物和方法
|
|
ES2528892T3
(es)
|
2012-07-30 |
2015-02-13 |
Nbe-Therapeutics Llc |
Identificación mediada por trasposición de proteínas de unión o funcionales específicas
|
|
WO2014031875A1
(en)
|
2012-08-23 |
2014-02-27 |
Seattle Genetics, Inc. |
Treatment of sickle cell disease and inflammatory conditions
|
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
MX2015005122A
(es)
|
2012-10-24 |
2015-10-29 |
Polytherics Ltd |
Conjugados de farmaco-proteina novedosos.
|
|
NO2789793T3
(https=)
*
|
2012-10-24 |
2018-01-27 |
|
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
AU2013364043B2
(en)
|
2012-12-21 |
2018-01-04 |
Seagen Inc. |
Anti-NTB-A antibodies and related compositions and methods
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
WO2014151649A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Alper Biotech, Llc |
Monoclonal antibodies to egfr, and uses therefor
|
|
EP2777714A1
(en)
|
2013-03-15 |
2014-09-17 |
NBE-Therapeutics LLC |
Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
EP2983674A4
(en)
|
2013-04-08 |
2017-05-10 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
PL3546572T3
(pl)
*
|
2013-05-13 |
2024-07-22 |
Cellectis |
Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
|
|
ES2826398T3
(es)
|
2013-10-15 |
2021-05-18 |
Seagen Inc |
Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
|
|
BR112016012538A2
(pt)
|
2013-12-17 |
2017-09-26 |
Novartis Ag |
peptídeos citotóxicos e conjugados dos mesmos
|
|
KR20230088389A
(ko)
|
2014-02-11 |
2023-06-19 |
씨젠 인크. |
단백질의 선택적 환원
|
|
SG10202001468UA
(en)
|
2014-02-17 |
2020-04-29 |
Seattle Genetics Inc |
Hydrophilic antibody-drug conjugates
|
|
CN111499753B
(zh)
|
2014-03-03 |
2022-10-21 |
高雄医学大学 |
双功能抗体及其用途
|
|
EP3119424A4
(en)
|
2014-03-19 |
2017-09-13 |
MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital |
Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
|
|
CN106132434A
(zh)
*
|
2014-04-07 |
2016-11-16 |
西雅图基因公司 |
抗‑cd19抗体和抗体‑药物偶联物的稳定制剂
|
|
SG11201607133QA
(en)
*
|
2014-04-08 |
2016-09-29 |
Seattle Genetics Inc |
Optimal dosing of a cd19-antibody drug conjugate
|
|
CN106573956A
(zh)
|
2014-06-13 |
2017-04-19 |
诺华股份有限公司 |
澳瑞他汀衍生物及其缀合物
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
TW201609152A
(zh)
|
2014-09-03 |
2016-03-16 |
免疫原公司 |
包含細胞結合劑及細胞毒性劑之偶聯物
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
SI3900742T1
(sl)
|
2014-09-11 |
2024-10-30 |
Seagen Inc. |
Ciljana dostava zdravilnih snovi, ki vsebujejo terciarne amine
|
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
|
EA201790719A1
(ru)
|
2014-09-26 |
2017-07-31 |
Макродженикс, Инк. |
Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
|
|
MA41414A
(fr)
*
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
EP3256493A4
(en)
*
|
2015-02-12 |
2018-07-11 |
Seattle Genetics, Inc. |
Combination therapy using a cd19-adc and vincristine
|
|
MX382582B
(es)
|
2015-03-18 |
2025-03-13 |
Seagen Inc |
Anticuerpos contra cúmulo de diferenciación 48 (cd48) y sus conjugados.
|
|
LT3302550T
(lt)
|
2015-05-26 |
2019-11-11 |
Morphosys Ag |
Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
|
|
WO2015151079A2
(en)
*
|
2015-06-20 |
2015-10-08 |
Hangzhou Dac Biotech Co, Ltd |
Auristatin analogues and their conjugates with cell-binding molecules
|
|
PT3316909T
(pt)
|
2015-06-30 |
2023-11-22 |
Seattle Genetics Inc |
Anticorpos anti-ntb-a e composições e métodos relacionados
|
|
SMT202100541T1
(it)
|
2015-08-21 |
2021-11-12 |
Morphosys Ag |
Combinazioni e loro usi
|
|
CN108348604B
(zh)
*
|
2015-09-08 |
2022-04-29 |
沃特世科技公司 |
用于分析抗体-药物缀合物的多维色谱方法
|
|
ES2980794T3
(es)
|
2015-09-15 |
2024-10-03 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
|
|
AU2016334063B2
(en)
|
2015-10-08 |
2023-05-25 |
Zymeworks Bc Inc. |
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
|
|
CN108290939B
(zh)
|
2015-10-16 |
2023-01-13 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
|
CN108367043A
(zh)
|
2015-12-04 |
2018-08-03 |
西雅图基因公司 |
季铵化的微管溶素化合物的缀合物
|
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
US20170233484A1
(en)
|
2016-02-17 |
2017-08-17 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
|
WO2017160954A1
(en)
|
2016-03-15 |
2017-09-21 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
|
KR20180134351A
(ko)
|
2016-03-25 |
2018-12-18 |
시애틀 지네틱스, 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
|
WO2017172981A2
(en)
*
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
RS62155B1
(sr)
|
2016-05-30 |
2021-08-31 |
Morphosys Ag |
Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata
|
|
SI3475303T1
(sl)
|
2016-06-27 |
2021-12-31 |
Morphosys Ag |
Formulacija protitelesa proti CD19
|
|
IL299099B2
(en)
|
2016-06-27 |
2025-07-01 |
Univ California |
Cancer treatment combinations
|
|
US20200230254A1
(en)
*
|
2016-07-22 |
2020-07-23 |
Seattle Genetics, Inc. |
Combination therapy using a cd19-adc and rchp
|
|
MX2019001302A
(es)
|
2016-08-09 |
2019-06-12 |
Seattle Genetics Inc |
Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
TWI835714B
(zh)
|
2016-10-18 |
2024-03-21 |
美商思進公司 |
菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
|
|
IL301786B2
(en)
|
2016-10-28 |
2025-09-01 |
Morphosys Ag |
Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
|
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
CN116672463A
(zh)
*
|
2017-02-17 |
2023-09-01 |
浙江特瑞思药业股份有限公司 |
靶向cd20抗体偶联药物的制备方法、抗体偶联药物及其用途
|
|
SG11201907870VA
(en)
|
2017-02-28 |
2019-09-27 |
Vor Biopharma Inc |
Compositions and methods for inhibition of lineage specific proteins
|
|
JP7337698B2
(ja)
|
2017-02-28 |
2023-09-04 |
シージェン インコーポレイテッド |
コンジュゲート化のためのシステイン突然変異抗体
|
|
AU2018237683A1
(en)
|
2017-03-24 |
2019-10-31 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
|
WO2018195339A1
(en)
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
WO2018201087A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
US11655307B2
(en)
|
2017-05-30 |
2023-05-23 |
The Board Of Regents Of The University Of Oklahoma |
Anti-doublecortin-like kinase 1 antibodies and methods of use
|
|
HRP20231229T1
(hr)
|
2017-05-31 |
2024-02-02 |
Morphosys Ag |
Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
|
|
WO2019011918A1
(en)
|
2017-07-10 |
2019-01-17 |
International - Drug - Development - Biotech |
TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
|
|
TWI799438B
(zh)
*
|
2017-08-10 |
2023-04-21 |
日商住友製藥股份有限公司 |
半星芒體衍生物及此等之抗體藥物複合體
|
|
ES2974288T3
(es)
|
2017-08-10 |
2024-06-26 |
Sumitomo Pharma Co Ltd |
Conjugados de anticuerpo-fármaco que incluyen un derivado de hemiasterlina
|
|
TWI878186B
(zh)
*
|
2017-09-21 |
2025-03-21 |
中國大陸商上海藥明生物技術有限公司 |
新型抗cd19抗體
|
|
AU2018337142B2
(en)
|
2017-09-22 |
2025-07-03 |
Wuxi Biologics Ireland Limited. |
Novel bispecific CD3/CD19 polypeptide complexes
|
|
JP7356727B2
(ja)
|
2017-10-12 |
2023-10-05 |
慶應義塾 |
アクアポリン３（ａｑｐ３）の細胞外ドメインに特異的に結合する抗ａｑｐ３モノクローナル抗体、及びその使用
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
MA50943A
(fr)
|
2017-12-01 |
2020-10-07 |
Seattle Genetics Inc |
Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
|
|
KR20200091901A
(ko)
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
|
WO2019119822A1
(en)
*
|
2017-12-23 |
2019-06-27 |
Uwell Biopharma Inc. |
Pharmaceutical chimeric receptor composition and method thereof
|
|
MA51583A
(fr)
*
|
2018-01-04 |
2020-11-11 |
Avidity Biosciences Inc |
Molécules d'acide nucléique hétéroduplex et leurs utilisations
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
CA3093731A1
(en)
|
2018-03-23 |
2019-09-26 |
Seattle Genetics, Inc. |
Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
TWI851577B
(zh)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
TW202019487A
(zh)
|
2018-08-06 |
2020-06-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物及微管蛋白抑制劑之組合
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
KR20200030337A
(ko)
|
2018-09-12 |
2020-03-20 |
주식회사 녹십자랩셀 |
종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
|
|
CA3118397A1
(en)
*
|
2018-11-01 |
2020-05-07 |
Shandong Newtime Pharmaceutical Co., Ltd. |
Bispecific antibody targeting cd3 and bcma, and uses thereof
|
|
WO2020160518A1
(en)
*
|
2019-02-01 |
2020-08-06 |
Memorial Sloan Kettering Cancer Center |
Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
|
|
WO2020163225A1
(en)
|
2019-02-05 |
2020-08-13 |
Seattle Genetics, Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
|
US12178879B2
(en)
|
2019-02-13 |
2024-12-31 |
Sumitomo Pharma Co., Ltd. |
Hemiasterlin derivative and antibody-drug conjugate thereof
|
|
US12312419B2
(en)
|
2019-02-13 |
2025-05-27 |
Sumitomo Pharma Co., Ltd. |
Hemiasterlin derivative having cysteine residue
|
|
JP7560255B2
(ja)
*
|
2019-02-13 |
2024-10-02 |
住友ファーマ株式会社 |
ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
|
|
WO2020213084A1
(en)
|
2019-04-17 |
2020-10-22 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
|
MX2021013101A
(es)
|
2019-05-03 |
2022-01-04 |
Morphosys Ag |
Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
|
|
CN110128551A
(zh)
*
|
2019-06-05 |
2019-08-16 |
上海科弈药业科技有限公司 |
一种针对cd19+肿瘤的多功能融合蛋白及其应用
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
US20220233709A1
(en)
|
2019-06-05 |
2022-07-28 |
Seagen Inc. |
Masked Antibody Formulations
|
|
US20220306727A1
(en)
|
2019-06-05 |
2022-09-29 |
Seagen Inc. |
Methods of Purifying Masked Antibodies
|
|
BR112022001045A2
(pt)
|
2019-07-22 |
2022-07-19 |
Seagen Inc |
Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
|
|
AU2020358859A1
(en)
|
2019-10-04 |
2022-05-12 |
Seagen Inc. |
Anti-PD-L1 antibodies and antibody-drug conjugates
|
|
US12544437B2
(en)
|
2019-10-04 |
2026-02-10 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant AAV
|
|
TWI865644B
(zh)
|
2019-10-31 |
2024-12-11 |
德商莫菲西斯公司 |
用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
|
|
US20210130461A1
(en)
|
2019-10-31 |
2021-05-06 |
Morphosys Ag |
Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
|
|
AU2020403273A1
(en)
*
|
2019-12-11 |
2022-06-30 |
Cullinan Oncology, Inc. |
Anti-CD19 antibodies and multi-specific binding proteins
|
|
IL293780A
(en)
*
|
2019-12-11 |
2022-08-01 |
Cullinan Man Inc |
Anti-serum albumin antibodies
|
|
WO2021178253A1
(en)
*
|
2020-03-03 |
2021-09-10 |
Systimmune, Inc. |
Anti-cd19 antibodies and methods of using and making thereof
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
WO2021207701A1
(en)
|
2020-04-10 |
2021-10-14 |
Seagen Inc. |
Charge variant linkers
|
|
US20230014026A1
(en)
|
2020-06-22 |
2023-01-19 |
Morphosys Ag |
Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
|
|
KR20230042518A
(ko)
|
2020-08-04 |
2023-03-28 |
씨젠 인크. |
항-cd228 항체 및 항체-약물 컨쥬게이트
|
|
MX2023003404A
(es)
|
2020-09-28 |
2023-03-31 |
Seagen Inc |
Anticuerpos anti-l1vi humanizados para el tratamiento del cancer.
|
|
EP4225794A1
(en)
|
2020-10-06 |
2023-08-16 |
Xencor, Inc. |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
IL302402A
(en)
|
2020-11-08 |
2023-06-01 |
Seagen Inc |
Combined treatment
|
|
US20220184208A1
(en)
|
2020-12-04 |
2022-06-16 |
Morphosys Ag |
Anti-cd19 combination therapy
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
AU2022238571A1
(en)
|
2021-03-18 |
2023-09-14 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
|
IL308296A
(en)
*
|
2021-05-07 |
2024-01-01 |
Viela Bio Inc |
Use of anti-CD19 antibody to treat myasthenia gravis
|
|
EP4370211A1
(en)
|
2021-07-14 |
2024-05-22 |
Seagen Inc. |
Antibody masking domains
|
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
WO2023108102A1
(en)
*
|
2021-12-10 |
2023-06-15 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Anti-lcn-2 antibodies as a treatment for eye disorders
|
|
IL315508A
(en)
|
2022-03-17 |
2024-11-01 |
Seagen Inc |
Camptothecin conjugates
|
|
CN119365219A
(zh)
*
|
2022-06-16 |
2025-01-24 |
艾伯维生物制药股份有限公司 |
抗cd19抗体药物缀合物
|
|
IL318787A
(en)
|
2022-08-17 |
2025-04-01 |
Incyte Corp |
Treatment including ANTI-CD19 antibodies and EZH2 modulators
|
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
|
CN120435319A
(zh)
|
2022-11-03 |
2025-08-05 |
思进公司 |
抗-avb6抗体和抗体-药物缀合物及其在癌症治疗中的用途
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
JP2026508145A
(ja)
|
2023-02-09 |
2026-03-10 |
ビーワン メディシンズ ワン ゲーエムベーハー |
自己安定化リンカーコンジュゲート
|
|
CN120957753A
(zh)
|
2023-03-23 |
2025-11-14 |
广州百济神州生物制药有限公司 |
生物活性结合物、其制备方法和其用途
|
|
CA3278900A1
(en)
|
2023-03-31 |
2024-10-03 |
AbelZeta Inc. |
BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
WO2025157132A1
(en)
|
2024-01-23 |
2025-07-31 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
|
|
TW202545567A
(zh)
|
2024-01-30 |
2025-12-01 |
美商思進公司 |
抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
|
|
TW202602929A
(zh)
|
2024-03-21 |
2026-01-16 |
美商思進公司 |
Ｃｄ２５抗體、抗體-藥物共軛體及彼等之用途
|
|
CN121622852A
(zh)
*
|
2026-02-05 |
2026-03-10 |
杭州康源食品科技有限公司 |
具有调节免疫补气血的蛋清蛋白来源小分子肽及其应用
|